09 May 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Since the autumn of 2012, the board of ONCOlog has worked to find buyers for the sale of the entire company or its assets. However, these efforts have not been successful and the ONCOlog board has therefore not seen any alternative left but to apply for the company to be declared bankrupt.
Allenex, which owns 14.9 percent of ONCOlog, has since mid-2011 changed its focus to include the transplantation area only. Allenex has since this strategic shift not financed ONCOlog in any way.
Therefore, the ONCOlog bankruptcy will not have any effect on Allenex` financial results. This is due to the fact that the Allenex holding in ONCOlog is already valued at zero and that no other commitments exist.
Stockholm-based Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. The information was submitted by Allenex pursuant to the EU Securities Markets Act and /or the Financial Instruments Trading Act for publication on May 08, 2013.